Emerging treatments and signaling pathway inhibitors.

Jean Y Tang, Ashfaq A Marghoob

Stanford University School of Medicine, Palo Alto, California, USA. tangy@stanford.edu

Seminars in cutaneous medicine and surgery 2011 Dec

filter terms:

A number of therapies that target components of the Hedgehog signaling pathway currently are in clinical trials. The specific molecules that seem most promising in basal cell carcinoma and a number of other cancers are those that target the Smoothened transmembrane protein. The pivotal phase II trials have been completed on the Smoothened inhibitor known as GDC-0449; five other agents (BMS-833923, LDE225, LEQ506, IPI926, and TAK-441) have also shown promise in animal studies and early clinical trials and have shown some efficacy in a variety of cancers that are affected by the Hedgehog signaling pathway. Copyright © 2011 Elsevier Inc. All rights reserved.

Citation

Jean Y Tang, Ashfaq A Marghoob. Emerging treatments and signaling pathway inhibitors. Seminars in cutaneous medicine and surgery. 2011 Dec;30(4 Suppl):S14-8